Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (271-280 of 361) with videos related to

Pageof 37
Sort By:
Nature Communications|July 30, 2021
An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancerRajdeep Das, Martin Sjöström, Raunak Shrestha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumorsPatricia M LoRusso, Roy S Herbst, Danny Rischin, et al.
Cancer Letters|June 26, 2016
An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancerGayatri Premasekharan, Elizabeth Gilbert, Ross A Okimoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical OutcomeDebraj GuhaThakurta, Nadeem A Sheikh, Li-Qun Fan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate CancerArun A Azad, Stanislav V Volik, Alexander W Wyatt, et al.
Journal of the National Cancer Institute|December 6, 2017
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate CancerAlexander W Wyatt, Matti Annala, Rahul Aggarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupHoward I Scher, Susan Halabi, Ian Tannock, et al.
Molecular Cancer Research : MCR|March 29, 2019
Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass HeterogeneityRahul R Aggarwal, David A Quigley, Jiaoti Huang, et al.
European Urology Oncology|May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE TrialKim N Chi, Elena Castro, Gert Attard, et al.
The New England Journal of Medicine|February 9, 2018
Apalutamide Treatment and Metastasis-free Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
Pageof 37

Showing results (271-280 of 361) with videos related to

Sort By:
Pageof 37
Nature Communications|July 30, 2021
An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancerRajdeep Das, Martin Sjöström, Raunak Shrestha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumorsPatricia M LoRusso, Roy S Herbst, Danny Rischin, et al.
Cancer Letters|June 26, 2016
An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancerGayatri Premasekharan, Elizabeth Gilbert, Ross A Okimoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical OutcomeDebraj GuhaThakurta, Nadeem A Sheikh, Li-Qun Fan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate CancerArun A Azad, Stanislav V Volik, Alexander W Wyatt, et al.
Journal of the National Cancer Institute|December 6, 2017
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate CancerAlexander W Wyatt, Matti Annala, Rahul Aggarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupHoward I Scher, Susan Halabi, Ian Tannock, et al.
Molecular Cancer Research : MCR|March 29, 2019
Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass HeterogeneityRahul R Aggarwal, David A Quigley, Jiaoti Huang, et al.
European Urology Oncology|May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE TrialKim N Chi, Elena Castro, Gert Attard, et al.
The New England Journal of Medicine|February 9, 2018
Apalutamide Treatment and Metastasis-free Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
Pageof 37